Comprehensive analysis of immunoglobulin and clinical variables identifies functional linkages and diagnostic indicators associated with Behcet’s disease patients receiving immunomodulatory treatment

Linlin Cheng1, Yang Li2, Ziyao Wu3, Liubing Li1, Chenxi Liu1, Jianhua Liu4, Jiayu Dai2, Wenjie Zheng3, Fengchun Zhang3, Liujun Tang3*, Xiaobo Yu2* and Yongzhe Li1*

Abstract

Background: Behcet’s disease (BD) is a relapsing systemic vascular autoimmune/inflammatory disease. Despite much effort to investigate BD, there are virtually no unique laboratory markers identified to help in the diagnosis of BD, and the pathogenesis is largely unknown. The aim of this work is to explore interactions between different clinical variables by correlation analysis to determine associations between the functional linkages of different paired variables and potential diagnostic biomarkers of BD.

Methods: We measured the immunoglobulin proteome (IgG, IgG1–4, IgA, IgA1–2) and 29 clinical variables in 66 healthy controls and 63 patients with BD. We performed a comprehensive clinical variable linkage analysis and defined the physiological, pathological and pharmacological linkages based on the correlations of all variables in healthy controls and BD patients without and with immunomodulatory therapy. We further calculated relative changes between variables derived from comprehensive linkage analysis for better indications in the clinic. The potential indicators were validated in a validation set with 76 patients with BD, 30 healthy controls, 18 patients with Takayasu arteritis and 18 patients with ANCA-associated vasculitis.

(Continued on next page)
Introduction
Behcet’s disease (BD) is a chronic and relapsing vascular autoimmune/autoinflammatory disease of unknown cause, displaying involvement of multiple organs [1, 2]. BD is highly prevalent in countries along the “Silk Road”; it can be induced by persistent and excessive immune reactions via autoantigen-activated dendritic cells and T or B cells and leads to endothelial cell damage and vasculitis [3]. Increases in human IgM, IgG and IgA levels have been found in BD patients, and the production of immunoglobulin isotypes is associated with mucocutaneous, ocular and systemic involvement in naïve active BD patients [4, 5].

Clinically, corticosteroids and immunosuppressants are employed in rheumatoid immune diseases to attenuate the inflammatory response and tissue damage and relieve clinical symptoms due to their anti-inflammatory and immunosuppressive effects on the immune system [4, 6–9]. However, their long-term use may lead to immune disorders [4, 7] and increased susceptibility to viral infection [10]. For example, Djaballah-Ider et al. found that corticosteroid therapy significantly reduced serum immunoglobulin isotype markers [4] and inflammatory mediators related to disease pathogenesis, including IL-18 and IFN-γ regardless of the clinical manifestations in BD [7]. Direskeneli et al. found that thalidomide has both anti-inflammatory and regulatory effects in BD, decreasing the levels of the TNF-α receptor, CD8/CD11b + T cells and natural killer cells in early treatment while increasing CD4 + CD45RO+ memory T and γδ + T cells in later treatment [9].

The systems in the human body (e.g., coagulation, inflammation, etc.) are known to execute their functions cooperatively instead of alone, which can be reflected by clinically measured variables [11–15]. For example, in a study of 48 participants with cirrhosis and nonalcoholic fatty liver disease, Niu et al. revealed the association of five plasma proteins (DPP4, ANPEP, TGFBI, PIGR and APOE) with liver enzymes through a global correlation map of clinical and proteomic data, implying their associations with cirrhosis and nonalcoholic fatty liver disease [12]. Nathan et al. investigated the personal, dense and dynamic data from 108 individuals during a 9-month period and generated a correlation network between clinical variables, proteomes and genome sequences, which revealed communities of related analytes associated with physiology and disease. For example, the negative correlation between levels of cystine in plasma and polygenic risk scores for inflammatory bowel disease revealed that genetic predisposition of diseases may be manifested by analyte changes and suggested that supplementation with cystine in a healthy population at high risk may stop the transition to disease by preventing inflammation and oxidative damage. Nathan proposed that measurement of personal data clouds over time can improve understanding of health and disease and are the essence of precision medicine.

Evidence has suggested that multiple pathological pathways are involved in BD with no single common denominator related with BD [2]. However, no common or dominant pathological factor for BD has been identified until now. Moreover, the correlations of clinical variables in BD and their associations with BD diagnosis, progression and therapy are largely unknown. The hypothesis of this work is to explore the interactions between different clinical variables by correlation analysis to determine the associations between the functional linkages of different paired variables and potential diagnostic biomarkers of BD. To address this issue, we first measured the immunoglobulin proteome (IgG, IgG1–4, IgA, IgA1–2) using a plasma microarray and performed a comprehensive correlation analysis of the immunoglobulin proteome and 29 clinical variables. We defined the physiological, pathological and pharmaceutical
relationships based on the correlations of all variables in the healthy controls (HCs) and BD patients without and with immunomodulatory therapy. Furthermore, we calculated the ratio changes between clinical variables to identify the specific indicators for the diagnosis of BD and differential diagnosis from other types of vasculitis.

Materials and methods
Demographic and clinical characteristics of subjects
All plasma samples were obtained from the Peking Union Medical College Hospital (Table 1), where BD patients were diagnosed according to the 1990 International Study Group (ISG) criteria [16] and the International Criteria for Behcet’s Disease (ICBD) [17], and patients with Takayasu arteritis (TA) and those with ANCA-associated vasculitis (AAV) were diagnosed respectively according to [18, 19]. Furthermore, all patients with BD were assigned to four groups according to medication use, which included BD patients without treatment (BD-N), treatment with corticosteroids (BD-C), treatment with immunosuppressants (BD-I) or treatment with both (BD-C&I). Patients using immunosuppressants are defined as those who are under drug treatments, including Azathioprine, Cyclosporine, Thalidomide, Cyclophosphamide, Leflunomide, Hydroxychloroquine and Tripterygium glycosides. Blood samples were anticoagulated with EDTA, centrifuged at 12,000 rpm for 10 min, and the upper plasma layer was collected and frozen at −80 °C until use. This study was approved by the Medical Ethics Committee of Peking Union Medical College Hospital (JS-2049), informed consent was obtained from all subjects. All research on humans was performed in accordance to the Declaration of Helsinki.

Quantification of the immunoglobulin proteome using plasma microarray
All plasma samples were retrieved from the −80 °C freezer, thawed on ice and centrifuged at 12,000 rpm for 10 min at 4 °C. Five microliters of each plasma sample was diluted with 0.02% BSA (phosphate-buffered saline, PBS, pH = 7.4) according to the immunoglobulin subtype (IgG2, IgG3, IgG4 and IgA2:10×; IgA1: 100×; IgG, IgA, IgG1: 500×). Standard immunoglobulin proteins were obtained commercially, including IgG (ZSGB-BIO, Beijing, China), IgA (Bersee Technology Co. Ltd., Beijing, China), IgG1 (Sino Biological Inc., Beijing, China), IgG2 (Sino Biological Inc.), IgG3 (Sino Biological Inc.), IgG4 (Sino Biological Inc.), IgA1 (Fitzgerald Industries International, Massachusetts, USA) and IgA2 (Fitzgerald Industries International). BSA (1 mg/ml) and 1x PBS (pH 7.4) were used as blank controls. All the samples were printed on the modified slide surface (CapitalBio Technology Co., Ltd., Beijing, China) in duplicate by a Smart-Arrayer™ 136 microarrayer (CapitalBio Technology Co., Ltd., Beijing, China).

Prior to the assay, the plasma microarray was first blocked with 1% BSA at room temperature for 1 h. The detection of immunoglobulin proteins in plasma was performed by incubation for 30 min with the appropriate fluorescein-labeled detection antibodies, including Donkey anti-hIgG(Fc) Alexa Fluor 555 and Rabbit anti-hIgA(Fc) Alexa Fluor 647 (Jackson Immuno Research, Pennsylvania, USA), Mouse Anti-Human IgG1 Hinge-Alexa Fluor® 488, Mouse Anti-Human IgG2 Fc-Alexa Fluor® 488, Mouse Anti-Human IgG3 Hinge-Alexa Fluor® 647, Mouse Anti-Human IgG4 Fc-Alexa Fluor® 488, Mouse Anti-Human IgG1- Alexa Fluor® 484, Mouse Anti-Human IgG2 Fc-Alexa Fluor® 484, Mouse Anti-Human IgG3 Hinge-Alexa Fluor® 647, Mouse Anti-Human IgG4 Fc-Alexa Fluor® 484, Mouse Anti-Human IgA1-Alexa Fluor® 647 and Mouse Anti-Human IgA2-Alexa Fluor® 488 (Southern-Biotech, Birmingham, USA). The unbound molecules were removed by washing the slide with 0.05% PBST three times and deionized water two times in the dark. Then, the resulting slide was air-dried and scanned by GenePix® 4300A (Molecular Devices, California, USA) at a wavelength of 488 nm (IgG1, IgG2 and IgA2), 532 nm (IgG or 635 nm (IgA, IgA1, IgG3 and IgG4).

The quantification of immunoglobulin proteins in plasma was performed by using a standard curve fitted with a 4- or 5-parameter logistic model using the “nplr package” in R as previously described [20].

Table 1

|                  | N  | BD-N | BD-C | BD-I | BD-C&I | HC | AAV | TA |
|------------------|----|------|------|------|--------|----|-----|----|
| **Discovery set**|    |      |      |      |        |    |     |    |
| Age(y)           | 15 | 35.40 ± 10.16 | 27.25 ± 13.18 | 30.50 ± 6.80 | 31.04 ± 9.800 | 49.17 ± 13.51 | / | / |
| Sex(M/F)         | 10/5 | 7/5 | 4/4 | 20/8 | 31/35 | / | / |
| ICBD             | 5.73 ± 2.63 | 5.75 ± 1.36 | 5.00 ± 1.53 | 6.643 ± 1.890 | / | / |
| **Validation set**| | | | | | | | |
| Age(y)           | 27 | 37.81 ± 11.60 | 34.20 ± 12.40 | 36.94 ± 13.69 | 38.40 ± 11.40 | / | / |
| Sex(M/F)         | 8/19 | 3/2 | 5/11 | / | 14/16 | 51.89 ± 14.07 | 33.94 ± 10.46 |
| ICBD             | 5.19 ± 1.62 | 6.60 ± 0.89 | 5.50 ± 1.32 | / | / | / |

*BD-N* BD patients not receiving corticosteroid or immunosuppressant treatment, *BD-C* BD patients receiving only corticosteroid treatment, *BD-I* BD patients receiving only immunosuppressant treatment, *BD-C&I* BD patients receiving both corticosteroid and immunosuppressant treatment.
Measurement of clinical variables
All plasma samples were removed from the −80 °C freezer, thawed on ice and centrifuged at 12,000 rpm for 10 min at 4 °C. The basic and clinical information of patients was obtained from the Hospital Information System of Peking Union Medical College Hospital, including age, sex, disease history, clinical symptoms and clinical treatment information with corticosteroids and/or immunosuppressants (Table 1). The results of the laboratory tests at the time of sample collection were obtained from the Laboratory Information Management System, including clinical chemistry, clinical immunology, hematology, etc. The abbreviations and full names of all clinical variables are shown in Table S1. Routine blood tests were completed by a Siemens ADVIA2120 or Sysmex XN9100 analyzer (Siemens, Munich, Germany; Sysmex America, Illinois, USA); ESR tests were completed by a Greiner MONITOR-S analyzer (Greiner Bio-one GmbH, Kremsmünster, Austria); CRP tests were completed by an Orion QuikRead go Instrument (Orion Corporation, Espoo, Finland); biochemical variables were completed by a Beckman AU5821 analyzer (Beckman Coulter, California, USA); and routine urinalysis was completed by Siemens Bayer Clinitek 500 analyzers (Siemens, Munich, Germany).

Statistical analysis
R version 3.5.2 and Prism 8.2.0 were used to perform all the statistical analyses. Descriptive statistics were presented as the mean ± standard deviation for continuous data or frequencies for categorical variables. Student’s t test or one-way ANOVA was applied to test the mean differences between two groups or multiple groups with normal distributions, respectively; otherwise, the Wilcoxon rank sum test or Kruskal-Wallis test was performed.

The linkage analysis of the immunoglobulin proteome and all variables was performed by calculating the Pearson’s or Spearman’s correlation coefficient between two variables according to their normality. Pearson’s correlation coefficient was performed when the data of both variables had a normal or log-normal distribution. Hierarchical clustering analysis of the correlation coefficient matrices was performed using Euclidean distance and the complete method in the heatmap package in R, with which the positively and negatively correlated variables were clustered together in a heatmap. A P value of < 0.05 was considered to be statistically significant.

In addition, ratios between every two clinical variables were calculated. Ratios more than one with significant difference when comparing BD-N and HC were retained for further comparison between groups in the validation set. A P value of < 0.05 was considered to be statistically significant.

Results
Quantification of the immunoglobulin proteome using a plasma microarray
A schematic illustration of high-throughput immunoglobulin proteome detection in plasma and the following data analysis is shown in Fig. 1. Briefly, all 129 plasma samples were printed onto a microscope slide using a microarray together with a series of concentrations of immunoglobulin protein standards. The resulting array was then detected by a fluorescein-labeled anti-immunoglobulin secondary antibody within 30 min. Standard curves were constructed by using the signals from immunoglobulin protein standards, with which the concentrations of immunoglobulin protein in all plasma samples can be quantified (Fig. S1). Statistical and correlation analyses were employed to identify the variable linkages that are related to BD and clinical treatment with corticosteroids and immunosuppressants, respectively.

A representative image of the fluorescence detection of the plasma microarray is shown in Fig. S2A. The signal of the immunoglobulin IgA standard was increased with increasing concentrations of the protein standards. The IgA in plasma samples displayed different signals on the microarray. The r correlation within and between different arrays was 0.91 and 0.96, respectively (Fig. S2B). The r correlations within arrays are calculated between blocks for different samples in the same array. In addition, we printed identical proteins on the top and bottom of the slide to evaluate the effect of printing location on plasma protein detection. The results indicate that the r correlation between the two locations was 1.00 for the immunological proteome (IgA, IgA1–2, IgG, and IgG1–4) (Fig. S2C, D). All these results demonstrate the high reproducibility of immunoassays using plasma microarrays.

Differential expression analysis of the plasma immunoglobulin proteome in BD patients receiving immunomodulatory therapy
Using this platform, we quantified the immunological proteome (IgA, IgA1–2, IgG, and IgG1–4) in the plasma of 66 HCs and 63 BD patients without and with corticosteroid and immunosuppressant treatment (Fig. 1). Prior to the statistical analysis, we analyzed the effect of age and sex on the expression of the immunoglobulin proteome. The results indicate that there was no correlation between immunoglobulin and age in either HCs or BD patients (Fig. S3A, B). The same results were obtained for sex and the immunoglobulin proteome in HCs (Fig. S4A). However, the expression of IgG4 in male BD patients was higher than that in female BD patients (P = 0.0326) (Fig. S4B).

Compared to the HCs, no significant changes were observed in the expression levels of IgG, IgG1–4, IgA and IgA1–2 in patients with BD-N (Fig. 2a, b). The
expression levels IgG1, IgG2 and IgG4 were suppressed by using combination treatment of corticosteroids and immunosuppressants (Fig. 2a, b) since statistical significance ($P < 0.05$) was achieved for IgG1 between BD patients without and with the combination of corticosteroids and immunosuppressant treatment, as well as for IgG2 and IgG4 between HCs and BD patients receiving the combination of corticosteroids and immunosuppressant treatment ($P < 0.05$, Fig. 2a). The results demonstrate that the immune system could be suppressed by corticosteroids and immunosuppressants through the regulation of immunoglobulin proteome expression.

Furthermore, we performed global linkage analysis to elucidate the potential mechanism promoted by the correlations of these immunological proteins during the progression of BD and the patients receiving immunomodulatory medication (Fig. 2c). We defined correlations ($r$) of 0.20–0.39 as weak linkage, 0.40–0.59 as moderate linkage, 0.60–0.79 as strong linkage and 0.80–1.0 as very strong linkage (Table S3). The red and blue colors of the circles represent positive and negative correlations, respectively. The size of the circle and intensity of the color are proportional to the correlation coefficients. We defined the physiological, pathological and pharmacological linkages according to the change of linkage under the disease and therapeutic situations. For example, the correlation of IgG-IgG1 ($r = 0.62 \sim 0.89$) and IgG-IgG2 ($r = 0.39 \sim 0.67$) remained constant in the HCs and BD patients without and with immunomodulatory therapy and were assigned as the physiological linkages (Fig. 2d). However, the correlations of IgA-IgG3 and IgA1-IgG3 were increased in BD patients compared with HCs and were assigned to the pharmacological linkage (Fig. 2e). Conversely, the correlation of pharmacological linkage, and IgA-IgG4 in the BD group was increased only in the patients who received immunomodulatory therapy (BD-C, BD-I and BD-C&I) (Fig. 2f).

Analysis of clinical variables in BD patients received immunomodulatory therapy

We then analyzed the changes in 29 variables, which were associated with inflammation, coagulation and nutrition, from clinical tests in HCs and BD patients without and with therapeutic treatment (Fig. 3 and Fig. S5). The abbreviations of their full names are shown in Table S1. First, we found that the clinical variables associated with inflammation are highly regulated in BD patients compared to HCs, including WBC, NEUT, CRP (Fig. 3a). The WBC level was high in BD patients treated with corticosteroids either alone or in combination with immunosuppressants ($P < 0.05$ for BD-C vs. HC). The same results were obtained for NEUT, CRP and ESR, which is in accordance with the function of immunosuppressants in inhibiting immunity and inflammation [8, 9, 21]. In addition, compared to ESR, CRP was significantly
Fig. 2 Analysis of the immunoglobulin proteome in the plasma of HCs and BD patients. a. Beeswarm plot of immunoglobulin proteome expression in HCs and BD patients with and without treatments; b. Comparison of immunoglobulin proteome changes in HCs and BD patients with and without treatments; c. Correlation analysis of immunoglobulin proteome in HC and BD patients with and without treatments; d-f are the changes in representative physiological, pathological and pharmacological linkages in HCs and BD patients with and without treatments, respectively. HC: healthy control; BD: Behcet's disease.
Fig. 3 (See legend on next page.)
elevated in the BD groups \( (P < 0.01) \), indicating that CRP is an effective indicator of inflammation in BD.

Second, in this study, we found no significant difference in nutrition variables between BD-N and HC \( (P < 0.05, \text{Fig. 3b}) \). However, the use of corticosteroids alone or in combination with the suppressants reduced the expression of albumin \( (\text{Alb, } P < 0.01 \text{ for BD-C vs. HC and BD-C&I vs. HC}) \) and therefore downregulated the total protein levels, especially in the BD-C&I group \( (\text{TP, } P < 0.01 \text{ for BD-C&I vs. HC/BD-N/BD-I}) \). Moreover, we found that Alb and TP decreased in patients with gastrointestinal involvement compared with those without gastrointestinal involvement and healthy controls, which may be due to impaired digestive function and a poor nutrition condition (Table S2).

Third, among these platelet variables associated with the coagulation process, MPV and PCT were observed to be significantly higher in the BD-N group than in the HC group \( (P < 0.01, \text{Fig. 3b}) \), indicating an increase in the volume of platelets and thus an enhanced ability of thrombosis [22]. Moreover, the use of corticosteroids increased the number of platelets \( (\text{PLT, } P < 0.01 \text{ for BD-C vs. HC and BD-C vs. BD-C&I}) \) and induced a corresponding increase in PCT while decreasing MPV in BD patients by reducing the destruction of platelets \( (P < 0.01 \text{ for BD-C vs. BD-N and BD-C vs. BD-I}) \) (Fig. 3c).

Fourth, we analyzed the changes in the ratio between these hematological indicators – neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR) in the HC and BD groups. NLR and PLR were increased in the BD groups compared with the HC group \( (P < 0.01) \), while LMR was decreased \( (P < 0.01) \) (Fig. 3d).

The heatmap analysis of these variables further demonstrated the increase in inflammation and coagulation as well as the decrease in nutritional status in BD patients without and with immunomodulatory treatment (Fig. 3e). All clinical variables with significant difference between BD-N and HC are listed in Table S2.

**Comprehensive linkage analysis of clinical variables in BD patients receiving immunomodulatory therapy**

Based on the previous finding, we speculated that all variables associated with our physiological system perform their functions cooperatively. To address this question, we comprehensively analyzed the linkages of all 37 variables in five groups of 129 samples by nonhierarchical clustering analysis, which led to 6845 linkages (Fig. 4a). The results indicate that the linkages of all variables were changed in the HCs and BD patients without and with immunomodulatory therapy, in which the linkages of the positive (red color) or negative (blue color) correlations were clustered and displayed as modules. For example, the variables of liver and renal functions were clustered together in the HC group, which is in accord with the collaborative function of the liver and kidneys to filter blood and process chemicals from food, medication and toxic substances. However, the kidneys could be damaged by BD, and some BD patients present with IgA nephropathy and amyloidosis [23, 24]. The results can be reflected in our correlation analysis in which the liver and renal function modules were separate in all BD groups (BD, BD-C, BD-I and BD-C&I).

Furthermore, the nonhierarchical clustering analyses revealed many physiological variable linkages that persisted in all HC and BD groups (Fig. 4b, Table 2). For example, a high positive correlation \( (r > 0.6) \) was observed for three physiological variable linkages \( (\text{HCT-HGB, MCH- MCV and PLT- PCT}) \) (Fig. 4c and d), confirming the functional association of these variables in oxygen transportation and coagulation [25, 26]. Conversely, A/G and ESR displayed a negative correlation in all HCs and BD patients \( (r = -0.96 \sim -0.73) \) (Fig. 4c and e), which confirmed their functional association with inflammation [27].

In addition, we noticed pathological and pharmacological variable linkages that were shown in BD patients without and with immunomodulatory treatment compared to the HCs (Table 2). For example, four linkages \( (\text{A/G-MCH, A/G-MCHC, Alb-uSG, TP-uSG}) \) were changed from none to positive correlations \( (r = 0.339 \sim 0.834) \) in the BD patients regardless of treatment (Fig. 5a-c), indicating the role of nutrition in BD pathogeneses [28–30]. As important inflammatory and thrombosis markers in BD, \( \text{WBC (r = 0.532, P = 0.04)} \) and \( \text{NEUT (r = 0.593, P = 0.02)} \) showed a significantly positively correlation with \( \text{PLT in BD patients without immunomodulatory treatment (Fig. 4, data not shown), suggesting their role of interactions in chronic infection, inflammation and tissue lesions in BD.}

The pharmacological linkages were clustered into five modules in BD patients under treatment (Fig. 5d). The correlation of linkages in the BD group was lower in modules #1–#4 and higher in module #5 than in the other groups. Compared to the HC group, the negative correlation of pharmacological linkages in module #2

(See figure on previous page.)

**Fig. 3** Changes in clinical variables in HC and BD patients. a-d. Beeswarm plot analysis of the changes in clinical variables associated with inflammation, coagulation, nutrition and the ratios of inflammatory cells in HCs and BD patients with and without treatments, respectively; e. Comparison of the changes in inflammation, coagulation, nutrition and the ratios of inflammatory cells in HCs and BD patients with and without treatments, respectively. HC: healthy control; BD: Behcet’s disease.
was decreased in BD patients and then increased in patients with treatments. The same results were observed in module #3 with positive correlations in HCs and treated patients. The linkages in module #1 changed from positive correlations in the HC group to negative correlations in treated groups, which is in contrast to module #4. Notably, the inflammation variables (CRP and ESR) showed no correlation with the nutritional variables (Alb and PA) in BD patients. However, their linkages were changed to positive correlations in BD patients after treatment with corticosteroids or immunosuppressants (Fig. 5d-f), which is in accord with previous reports [31, 32] and confirms the association between the increase in inflammation and poor nutrition. However, the clinical utility of these pharmacological linkages has to be validated in different cohorts of BD patients with the follow-up information.

**Analysis of ratio changes between clinical variables in patients with BD and healthy and disease controls**

Based on the linkage analysis, we further calculated the ratios between every two clinical variables to investigate
| Type                      | Linkage             | HC     | BD-N   | BD-C   | BD-I   | BD-C&I |
|--------------------------|---------------------|--------|--------|--------|--------|--------|
| Physiological linkage    | A/G-MCH             | 0.058  | 0.595  | 0.491  | 0.632  | 0.506  |
| Physiological linkage    | A/G-MCHC            | 0.053  | 0.499  | 0.779  | 0.783  | 0.339  |
| Physiological linkage    | A/G-PLT             | 0.009  | 0.399  | 0.015  | 0.077  | 0.0667 | -0.176 |
| Physiological linkage    | Alb-DBil            | 0.037  | 0.116  | 0.424  | 0.818  | 0.192  |
| Physiological linkage    | Alb-IgG1            | 0.009  | 0.42   | 0.049  | 0.055  | 0.335  |
| Physiological linkage    | Alb-uSG             | 0.042  | 0.834  | 0.584  | 0.783  | 0.439  |
| Physiological linkage    | Cr-upH              | -0.092 | -0.377 | -0.25  | -0.447 | -0.426 |
| Physiological linkage    | HGB-TP              | 0.104  | 0.256  | 0.281  | 0.812  | 0.345  |
| Physiological linkage    | IgA2-IgG            | 0.051  | 0.493  | 0.147  | 0.595  | 0.209  |
| Physiological linkage    | IgG-LY%             | 0.053  | 0.157  | 0.28   | 0.333  | 0.333  |
| Physiological linkage    | IgG1-IgG2           | 0.009  | 0.304  | 0.168  | 0.262  | 0.481  |
| Physiological linkage    | LY%-WBC             | -0.059 | -0.215 | -0.771 | -0.667 | -0.176 |
| Physiological linkage    | MCH-MONO            | 0.061  | 0.266  | 0.671  | 0.156  | 0.5    |
| Physiological linkage    | MCH-PLT             | 0.069  | -0.181 | -0.504 | -0.743 | 0.196  |
| Physiological linkage    | MCHC-PLT            | -0.042 | -0.215 | -0.634 | -0.167 | 0.104  |
| Physiological linkage    | MCV-PLT             | -0.056 | -0.218 | 0.601  | -0.539 | -0.22  |
| Physiological linkage    | PDW-TP              | -0.006 | -0.35  | -0.049 | -0.493 | 0.592  |
| Physiological linkage    | BASO-Cr             | 0.004  | 0.365  | 0.172  | 0.11   | 0.37   |
| Physiological linkage    | BASO-LY%            | 0.003  | 0.246  | 0.244  | 0.333  | 0.333  |
| Physiological linkage    | IgG-MCHC            | 0.011  | 0.293  | 0.445  | -0.381 | 0.329  |
| Physiological linkage    | IgG2-LY             | -0.074 | 0.379  | 0.49   | 0.262  | 0.487  |
| Physiological linkage    | MCHC-MONO           | 0.077  | -0.264 | -0.473 | -0.643 | 0.613  |
| Pharmacological linkage   | uSG-TP              | 0.049  | 0.64   | -0.682 | -0.816 | 0.12   |
| Pharmacological linkage   | uSG-TP              | 0.184  | 0.781  | 0.463  | 0.816  | 0.439  |
| Pharmacological linkage   | A/G-PA              | 0.1286 | 0.028  | 0.685  | 0.377  | 0.458  |
| Pharmacological linkage   | A/G-uSG             | 0.182  | 0.024  | 0.425  | 0.258  | 0.067  |
| Pharmacological linkage   | EOS-IgG4            | -0.009 | -0.014 | -0.063 | -0.321 | 0.27   |
| Pharmacological linkage   | HCT-IgG4            | 0.244  | -0.015 | -0.334 | -0.436 | 0.109  |
| Pharmacological linkage   | IgA-IgG4            | -0.4763| -0.032 | 0.153  | 0.986  | 0.337  |
| Pharmacological linkage   | IgG-IgG4            | 0.026  | 0.007  | 0.307  | 0.067  | 0.271  |
| Pharmacological linkage   | IgG-LY              | 0.1786 | -0.14  | -0.8   | -0.551 | 0.394  |
| Pharmacological linkage   | MCHC-PA             | -0.4639| -0.027 | -0.338 | -0.899 | 0.524  |
| Pharmacological linkage   | A/G-DBil            | -0.05007| 0.014  | 0.041  | 0.841  | 0.056  |
| Pharmacological linkage   | A/G-TBil            | 0.056  | 0.009  | 0.402  | 0.036  | 0.539  |
| Pharmacological linkage   | CRP-PLT             | 0.364  | 0.032  | 0.577  | 0.778  | 0.518  |
| Pharmacological linkage   | HGB-MCHC            | 0.418  | 0.02   | 0.149  | 0.79   | 0.488  |
| Pharmacological linkage   | IgG4-TP             | 0.079  | 0.093  | 0.319  | 0.619  | 0.444  |
| Pharmacological linkage   | PDW-TBil            | 0.143  | 0.002  | 0.487  | -0.143 | 0.033  |
| Pharmacological linkage   | ESR-WBC             | 0.2504 | 0.088  | 0.632  | 0.771  | 0.351  |
| Pharmacological linkage   | IgA-NEUT            | -0.178 | -0.028 | -0.6   | -0.108 | 0.304  |
| Pharmacological linkage   | BASO-NEUT           | 0.113  | 0.002  | 0.36   | 0.986  | 0.065  |
| Pharmacological linkage   | ESR-PA              | 0.143  | 0.042  | 0.35   | 0.986  | 0.341  |
| Pharmacological linkage   | IgG2-MCHC           | 0.07099| 0.06   | -0.61  | -0.464 | 0.589  |
| Pharmacological linkage   | Alb-CRP             | 0.2121 | 0.005  | -0.874 | -0.429 | -0.697 |
their coordinated changes. In total, there were 152 pairs of variables with significant fold changes of more than one between BD-N and HC (Table S4).

To validate the significant changes between two clinical variables, the immunoglobulin expression and clinical variables in a validation set consisting of BD-N (n = 27), BD-C (n = 5), BD-I (n = 16), HC (n = 30), AAV (n = 18), and TA (n = 18) (Table 1) were measured. Significant ratio changes for 8 pairs of variables were ultimately validated in the discovery set (Table S5), among which TP/MCV, PCT/MONO, TP/MCH, and TP/MCHC were found to be significantly increased in BD compared with HC, AAV and TA in the discovery and validation sets (P < 0.05, Fig. 6, Table 3; Table S5), regardless of immunomodulatory therapy (P > 0.05, Table 3; Table S5). In addition, these biomarkers were not affected by corticosteroids and immunosuppressants (P > 0.05 for BD-N vs. BD-C and P > 0.05 for BD-N vs. BD-I, Table S5). Furthermore, we investigated changes in the ratio of different BD subsets and found that due to the decreased TP levels, TP/MCV, TP/MCH and TP/MCHC were decreased in BD patients with gastrointestinal involvement compared with those without gastrointestinal involvement and healthy controls. Conversely, significant increases in TP/MCV, TP/MCH and TP/MCHC were found in BD patients without gastrointestinal involvement compared to healthy controls. MPV/HCT and MPV/HGB were also increased in BD patients (Table S5), especially the BD subset with blood system involvement, including five patients with anemia or myelodysplastic syndrome (Table S5), indicating anemia and potential disorder of blood cell morphology.

**Discussion**

BD is an inflammatory disease of unknown etiology that affects the epidermal, mucocutaneous, vascular, ophthalmologic, gastrointestinal, pulmonary, and central
nervous systems. Corticosteroids and immunosuppressants are frequently employed clinically to treat BD patients by regulating inflammation and immune disorders. As an option for long-term treatment for autoimmune diseases [33], immunosuppressants have an inhibitory effect on the immune response to weaken attacks on body’s own tissue by inhibiting the proliferation and function of T cells or B cells [34]. In contrast, corticosteroids work quickly but have significant side effects. Corticosteroids can affect almost all kinds of immune cells and multiple points of the immune response. For example, they prevent lymphocyte recycling and the production of antibody-producing and cytotoxic effector cells, but they also have significant anti-inflammatory effects. They inhibit the adhesion of neutrophils to vascular endothelium in inflammatory sites and inhibit monocyte function, among other effects [35]. However, the pathogenesis of BD and its therapeutic influence by immunomodulatory medication are largely unknown. To address this question, we comprehensively measured and analyzed the changes in clinical variables related to immunity, inflammation, coagulation and nutrition in HCs and BD patients without and with immunomodulatory medication.

We observed an overall increase in immunoglobulin proteome expression in BD patients without treatment (Fig. 2), which demonstrates the existence of an immune disorder during BD development [4]. However, the expression of the immunoglobulin proteome, especially IgG1, IgG2 and IgG4, can be suppressed by corticosteroids and immunosuppressants. The results can be further confirmed by the correlation analysis, in which the correlations of pathological linkages (IgA-IgG3 and IgA1-IgG3) were increased in the BD group and decreased under immunomodulatory therapy (Figs. 2c and 3e). The results demonstrate that corticosteroids and immunosuppressants exert their effects by inhibiting immune and inflammatory responses [4, 7].

The same results were observed in inflammation, in which WBC and NEUT were significantly increased in the BD groups, which was consistent with the functions of WBC and NEUT in mediating vessel damage through enhanced migration in the circulatory system. While corticosteroids are used to inhibit inflammation and the immune response in certain clinical situations, they may also cause an increase...
in the WBC count and predominantly neutrophils (NEUT) mainly by the demargination of the neutrophils from the endovascular lining [36, 37]. In addition, the use of corticosteroids may promote the maturation of neutrophils in the bone marrow and mobilization into the blood circulation by expression of key receptors such as Annexin A1 [38, 39], as also observed for the pathological link of BASO-LY% and LY%-WBC. Although immunosuppressants such as azathioprine are reported to causes dose-related bone marrow suppression and leukopenia [40], we did not observe significant difference in blood cells in this study. All these results suggest that clinical evaluations of

![Fig. 6](image-url) Significant ratio changes between BD and HC and disease controls in the discovery and validation sets. a. Boxplot of the levels of the four ratios in HCs and BD patients with and without treatments in the discovery set. b. Boxplot of the levels of the four ratios in HCs, BD patients with and without treatments, and patients with ANCA-associated vasculitis and Takayasu arteritis in the validation set. HC: healthy controls; BD-N: BD patients not receiving corticosteroid or immunosuppressant treatment; TA: Takayasu arteritis; AAV: ANCA-associated vasculitis

| Discovery set BD-N vs. | Validation set: BD-N vs. |
|-----------------------|--------------------------|
| **Discovery set BD-N vs.** | **Validation set: BD-N vs.** |
| **HC** | **HC** | **AAV** | **TA** |
| **TP/MCV** | * | 1.0579355 | * | 1.0712601 | *** | 1.2863344 | * | 1.120872 |
| **PCT/MONO** | **| 1.425393 | * | 1.5778604 | * | 1.6435788 | * | 1.5614405 |
| **TP/MCH** | **| 1.0904052 | * | 1.1113632 | *** | 1.2590039 | * | 1.0998654 |
| **TP/MCHC** | **| 1.0933265 | **| 1.1448527 | *** | 1.2285696 | * | 1.091615 |

* P < 0.05. ** P < 0.01. *** P < 0.001

Table 3 Rations significantly increased in BD patients without corticosteroid and immunosuppressant therapy compared with healthy controls and disease controls in both the discovery and validation sets.
inflammation should consider medication use as well as the clinical symptoms and signs of the patients.

Inflammation may cause damage to the vessel wall and initiate the coagulation pathway and thrombosis [22, 41]. Platelets could be hyperactivated under inflammation, after which granules are released to further promote coagulation and inflammation [42]. In this study, upregulation of MPV in BD patients and its downregulation by corticosteroids were observed (Fig. 3). MPV reflects alterations in the morphology of platelets. Elevated MPV means larger platelets with more dense granules that are therefore more thrombogenic than smaller ones, and it is a marker of platelet function and is involved in thrombosis and vascular damage in BD [43, 44]. In contrast, the change in PLT was not obvious, as changes in MPV and PCT can be observed before detectable changes in platelets [22]. There is also growing evidence that platelets are not only involved in fatal vascular events but also function in disease progression by interacting with neutrophils. Schrottmaier et al. proposed that direct interaction of platelets with neutrophils leads to neutrophil activation, recruitment and formation of neutrophil extracellular traps, further promoting the progression of vascular pathologies [42]. Pamuk et al. found significantly higher levels of platelet-neutrophil complexes in BD patients with major vascular involvement than in those without vascular involvement and healthy controls [45]. Consistently, interaction between WBCs or neutrophils and platelet was observed in this research in BD patients based on their positive correlation (Fig. 4). Platelets also showed the highest affinity for other innate and adaptive immune cells, including monocytes (as discussed in the next section) and lymphocytes, by soluble mediators [42]. In this study, the pharmacological linkages of LY%-PLT and CRP-PLT further suggest that integrative analysis of granulocytes, platelets and related variables is likely to provide a comprehensive understanding of disease activity, thrombotic potential and potential tissue damage.

Based on linkage analysis, we further constructed a novel method according to the ratio changes between two clinical variables and demonstrated that four ratios – TP/MCV, PCT/MONO, TP/MCH, and TP/MCHC – have higher value in BD than in HC, TA and AAV, suggesting these four ratios as potential diagnostic indicators for BD. PCT, which is produced from PLT and MPV, reflects the total platelet mass [46]. In our research, PCT and MPV were significantly increased in BD. Platelets play an important role in the pathogenesis of thromboembolic diseases. Platelets are more reactive in BD patients than in normal controls, which may contribute to the tendency for thrombosis. Moreover, increased MPV in an inflammatory state contributes to thrombosis, which may be an independent risk factor for vascular involvement in BD [47]. Evidence has shown that monocytes in BD patients are activated and produce proinflammatory cytokines, causing increased adhesion of neutrophils to endothelial cells and chronic inflammation [48]. Interactions between platelets and monocytes is also reported to relate to major vascular involvement in BD [45], and platelets may induce monocyte differentiation into a more inflammatory phenotype [49]. The higher value of PCT/MONO, consisting of platelets and monocytes, confirms the potentially close interaction between platelets and monocytes [42]. This has been highlighted as an important pathophysiological link between inflammation, thrombosis and endothelial activation [50], such as the concordance of platelets and monocytes in immune-thrombosis. Moreover, platelets are reported to interact with monocytes to propagate their differentiation into macrophages, and when activated, platelets stimulate monocytes to leave the blood vessel and enter tissues, causing a higher level of PCT/MONO [51]. We propose that a higher level of PCT/MONO, representing aggregates and interaction between platelet and monocyte, is a potentially attractive and easily accessible marker in BD [42].

MCV, MCH, and MCHC are useful biomarkers in the evaluation of anemia. MCV indicates the mean size of red blood cells, while MCH and MCHC indicate the mean amount and the mean concentration of hemoglobin in each red blood cell, respectively. It has been reported that chronic anemia is common in BD patients, especially with intestinal involvement [52, 53], with contributors like bone marrow failure [54] or serum prohepcidin and hepcidin, whose levels are also closely associated with disease activity [55]. It is likely that the increasing trend of total protein and/or decreases in MCV, MCH or MCHC lead to high levels for the three ratios. However, our study demonstrated that corticosteroids and immunosuppressants do not function by decreasing these higher ratios, illustrating the stability of these indicators. However, other factors involved and the specific mechanisms of these interactions remain to be elucidated in future studies.

There are several limitations in our research. First, the coregulatory mechanisms of clinical variables through physiological, pathological and pharmacological linkages are not well understood and should be carefully interpreted according to the clinical symptoms of BD patients. Second, the numbers of samples and patients’ information employed in this study were limited. In the future, we will include more information to match the backgrounds of control patients and verify the utility of these functional linkages in diagnosis and prognosis in larger cohorts.
Conclusion
In this work, we measured and performed a comprehensive correlation analysis of clinical variables for BD patients with appropriate therapeutic treatment. It is important for clinicians to be aware of the effect of immunomodulatory therapy on laboratory tests for an appropriate interpretation of patients’ conditions and to reduce unnecessary medical examinations or therapies. Moreover, we conceptually defined the physiological, pathological and pharmacological linkages of these variables and elucidated their functions for clinical application. The linkages found in our study highlight the close interactions between several markers in BD. Mutual regulation of platelets and different immune cells or other inflammatory markers promotes the development and exacerbation of vascular abnormalities in the pathogenesis of BD, suggesting the potential of combined anti-coagulation and anti-inflammatory therapy in BD. The ratio changes among PLT/MONO, TP/MCV, TP/MCH and TP/MCHC are stable diagnostic indicators for BD regardless of the medication status. These results demonstrate the utility of our approach in elucidating the potential mechanism of BD pathogenesis and therapeutic effects as well as in identifying potential biomarkers to assist BD diagnosis and therapies in the future.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12865-021-00403-1.

Additional file 1: Table S1 Abbreviations and full names of the laboratory tests used in this study. Table S2 Variables with significant differences between healthy controls and BD patients not treated with corticosteroids and immunosuppressants therapy. Table S3 Spearman correlation (r and P value) analysis of the immunoglobulin proteome in HCs and BD patients with and without immunomodulatory therapy. Table S4 Ratios with significant differences and fold change more than one between healthy controls and BD patients not treated with corticosteroids and immunosuppressants therapy in the discovery set. Table S5 Ratios with significant differences between BD patients not treated with corticosteroids and immunosuppressants therapy, healthy control and disease controls in both the discovery set and validation set. Fig. S1. Standard curves for the quantification of eight immunoglobulin isotypes. Fig. S2. The assay performance of the plasma microarray in the detection of the immunoglobulin proteome. Fig. S3. Correlation analysis between immunoglobulins and age in H(CA) and BD(B). Fig. S4. Beeswarm plots of immunoglobulin proteome expression between sex groups in H(CA) and BD(B). Fig. S5. Comparison of laboratory tests in HC and BD patients with and without immunomodulatory therapy.

Acknowledgements
Not applicable.

Authors’ contributions
Cheng L. collected the plasma samples, performed the experiments, wrote the main manuscript and drew figures. Li Y. drew figures. Wu Z, Li L and Liu C collected the plasma samples and clinical information. Liu J and Dai J guided the experiments. Zheng W and Zhang F diagnosed the disease. Li Y, Yu X and Tang L supervised the work and edited the manuscript for the logical relationship. Li Y, Yu X and Tang L reviewed the figures for logical concepts. Yu X and Tang L guided the design and reviewed the data during the revision. The authors read and approved the final manuscript.

Funding
This work was supported by the National Natural Science Foundation of China (81673040, 31870823, 81671618, 81871302), the National Program on Key Basic Research Project (2017YFC0906703) and 2018ZX09303003, the State Key Laboratory of Proteomics (SKLP-O201307 and SKLP-K201505), and the CAMS Initiative for Innovative Medicine (2017-ICM-3-001, 2017-ICM-B6R-01). This work is supported by Beijing Key Clinical Specialty for Laboratory Medicine - Excellent Project (No. ZKQ201000).

Availability of data and materials
All data generated or analyzed during this study are included in this published article (and its supplementary information files).

Ethics approval and consent to participate
This study was approved by the Medical Ethics Committee of Peking Union Medical College Hospital. This manuscript does not contain data for any individual person.

Consent for publication
Not applicable.

Competing interests
The authors declare they have no competing interests.

Author details
1Department of Clinical Laboratory, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, No.1, Shuaijiaxian Fang Jin Ping Dong Cheng District, Beijing 100730, China. 2State Key Laboratory of Proteomics, Beijing Proteome Research Center, National Center for Protein Sciences (Beijing), Beijing Institute of LifeSciences, No. 38, Life Science Park Road Changping District, Beijing 102206, China. 3Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Peking Union Medical College and Chinese Academy of Medical Sciences, Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing 100730, China. 4Department of Laboratory Medicine, Shengjing Hospital of China Medical University, Shenyang 110004, China.

Received: 24 November 2020 Accepted: 29 January 2021
Published online: 22 February 2021

References
1. Davatchi F, Shafam T, Cham-Davatchi C, Shams H, Nadji A, Akhlaghi M, Faezi T, Ghodsi Z, Faridard A, Ashofteh F, Sadeghi AB. Behchet’s disease: from east to west. Clin Rheumatol. 2010;29:823–33.
2. Yazici H, Seyahi E, Hatemi G, Yazici Y. Behdet syndrome: a contemporary view. Nat Rev Rheumatol. 2018;14:107–19.
3. Direskeneli H, Saruhan-Direskeneli G. Disease mechanisms. In: Yazici H, editors. Behcet’s Syndrome. New York, NY: Springer New York; 2010. p. 243–64.
4. Djaballah-Ider F, Djaballah A, Djareba Z, Chab S, Toull-Boukoffa C. Auto-immunity profile evaluation during different clinical manifestations of Behchet disease in Algerian patients: effect of corticosteroid treatment. Inflammopharmacology. 2019;27:1113–22.
5. Cho SB, Zheng Z, Ahn KJ, Choi MJ, Cho S, Kim DY, Lee HS, Bang D. Serum IgA reactivity against GroEL of Streptococcus sanguinis and human heterogeneous nuclear ribonucleoprotein A2/B1 in patients with Behchet disease. Br J Dermatol. 2013;168:977–83.
6. Youssif J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin N Am. 2016;42:157–76 ix-x.
7. Djaballah-Ider F, Djareba Z, Chenri M, Dammenne-Debbieh N, Lounis D, Belguendouz H, Medour Y, Chab S, Toull-Boukoffa C. Influence of corticosteroid therapy on IL-18 and nitric oxide production during Behchet’s disease. Inflammopharmacology. 2018;26:725–35.
8. Bohler C, Radner H, Smolen JS, Aletaha D. Serological changes in the course of traditional and biological disease modifying therapy of rheumatoid arthritis. Ann Rheum Dis. 2013;72:241–4.
50. Glezeva N, Gilmer JF, Watson CJ, Ledwidge M. A central role for monocyte-platelet interactions in heart failure. J Cardiovasc Pharmacol Ther. 2016;21:245–61.
51. Kral JB, Schrottmaier WC, Salzmann M, Assinger A. Platelet interaction with innate immune cells. Transfus Med Hemother. 2016;43:78–88.
52. Ye J-F, Chen Y, Gai J-F, Shen Y, Zou J, Guan J-L. Incidence and risk factors for anemia among newly-diagnosed intestinal Behcet’s disease patients. J Natl Med Assoc. 2019;111:407–12.
53. Çiçek D, Kandi B, İlhan N, Bakar Dertilioğlu S, Demir B. Frequency of Anemia of Chronic Disease in Patients with Behcet’s Disease. TURKDERM - Turkish Arch Dermatol Venereol. 2007;41:121–4.
54. Ahn JK, Cha HS, Koh EM, Kim SH, Kim YG, Lee OK, Yoo B. Behcet’s disease associated with bone marrow failure in Korean patients: clinical characteristics and the association of intestinal ulceration and trisomy 8. Rheumatology. 2008;47:1228–30.
55. Dagli M, Yilmaz S, Sivrikaya A, Celik G. The role of Prohepcidin and Hepcidin in Anemia associated with Behçet’s disease. In: UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi; 2012. p. 22.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.